ITRM

Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing anti-infectives for multi-drug resistant pathogens. The company's lead product candidate, sulopenem, is an oral and intravenous penem antibiotic designed to treat serious bacterial infections. Iterum is conducting clinical trials targeting uncomplicated urinary tract infections and complicated urinary tract infections caused by resistant organisms. The company aims to address the growing global health threat of antimicrobial resistance.